EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 Inhibitor

Frédéric Vallée iD, Matias Casás-Selves, Monica Bubenik, Martin Duplessis, Boubacar Sow, Catalina Suarez, Bruno Sangiorgi, Li Li, Marc Hyer, Robert Papp, Marie-Eve Leclaire, Alexander L Perryman und 26 weitere

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c00529 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Frédéric Vallée und 37 weiteren Autor:innen. Beteiligte Einrichtung: Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada. Hauptthemen laut MEDLINE: Antineoplastic Agents, Drug Discovery, Protein Kinase Inhibitors, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Canadian Institutes of Health Research, Chemical Computing Group, Inc. Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PLK4 is a cell cycle-regulated kinase important for the biogenesis of centrioles and is known to be synthetically lethal with TRIM37 gene amplification. Previous attempts to inhibit PLK4 have been hampered by selectivity or ADME liabilities. The known inhibitor Centrinone B, while potent and selective, is metabolically unstable and lacks oral bioavailability. Assisted by structure-based drug design (SBDD), dramatic improvements in potency, selectivity and ADME properties were made to this structure, resulting in the identification of RP-1664, a potent inhibitor of PLK4 with an excellent pharmacokinetic profile in preclinical species. Kinome profiling demonstrated exquisite selectivity over related kinases, including AURKA/B and PLK1. RP-1664 disrupts centriole biogenesis in cancer cells, modulates pharmacodynamic readouts of PLK4 activity in xenograft tumor tissues, and is efficacious in multiple TRIM37-amplified xenograft models. This first-in-class clinical candidate is currently being evaluated in Phase 1 clinical trials (NCT06232408) for treatment of advanced solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsDrug DiscoveryProtein Kinase InhibitorsProtein Serine-Threonine KinasesAnimalsHumansMiceRatsAdministration, OralBiological AvailabilityCell Line, TumorStructure-Activity RelationshipXenograft Model Antitumor Assays

Substanzen

Antineoplastic AgentsPLK4 protein, humanProtein Kinase InhibitorsProtein Serine-Threonine Kinases

Autor:innen und Institutionen

  • Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada.
  • Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5G 1X5, Canada.
  • Repare Therapeutics, 1 Broadway, 15th Floor, Cambridge, Massachusetts 02142, United States.
  • Sygnature Discovery, 2350 rue Cohen Suite 201, Ville St-Laurent, QC H4R 2N6, Canada.
  • Departments of Biochemistry and Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada.

ORCID-Profile: Frédéric Vallée, Victor Pau, Pavel Mader, Frank Sicheri, W Cameron Black

Förderung

  • Canadian Institutes of Health Research
  • Chemical Computing Group, Inc. Canada

Zitieren

APA

Vallée, F., Casás-Selves, M., Bubenik, M., Duplessis, M., Sow, B., Suarez, C., Sangiorgi, B., Li, L., Hyer, M., Papp, R., Leclaire, M. E., Perryman, A. L., Liu, B., Surprenant, S., Mochirian, P., Pau, V., Maderova, Z., Mader, P., Yin, S. Y., …, & Black, W. C. (2025). Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 Inhibitor. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c00529

Vancouver

Vallée F, Casás-Selves M, Bubenik M, Duplessis M, Sow B, Suarez C, et al. Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 Inhibitor. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c00529

BibTeX
@article{Valle2025,
  author = {Vallée, Frédéric and Casás-Selves, Matias and Bubenik, Monica and Duplessis, Martin and Sow, Boubacar and Suarez, Catalina and Sangiorgi, Bruno and Li, Li and Hyer, Marc and Papp, Robert and Leclaire, Marie-Eve and Perryman, Alexander L and Liu, Bingcan and Surprenant, Simon and Mochirian, Philippe and Pau, Victor and Maderova, Zdenka and Mader, Pavel and Yin, Shou Yun and Goodfellow, Elliot and Roulston, Anne and Stocco, Rino and Godbout, Claude and Baruah, Prasamit and Bonneau-Fortin, Alexanne and Schonhoft, Joseph D and Nejad, Parham and Norman, David and Truong, Vouy Linh and Crane, Sheldon and Attia, Mohamed A and Mao, Daniel and Sicheri, Frank and Marshall, C Gary and Zimmermann, Michal and Bendahan, David and Gallant, Michel and Black, W Cameron},
  title = {Discovery of RP-1664: A First-in-Class Orally Bioavailable, Selective PLK4 Inhibitor},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c00529}
}
Kostenlos starten →